First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 924-930, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-772341
ABSTRACT
Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor has become one of the important treatment options for patients with advanced non-small cell lung cancer (NSCLC). However, only a small subset of patients with NSCLC can currently receive single-agent PD-1 inhibitors as first-line therapy, for the limitations of population selection exclude most patients from immuno-oncology (IO) monotherapy. In order to expand the candidate population for IO first-line treatment and make more newly diagnosed patients benefit from IO treatment, a series of studies are focusing on the combination of IO and other drugs in NSCLC. We reviewed the latest clinical data of IO first-line combination therapy in recent years, suggesting that on the basis of PD-1/PD-L1 inhibitors, combined with other IO, chemotherapy, anti-angiogenic drugs, targeted therapy or radiotherapy may produce synergistic anti-tumor effects. It is expected to benefit more newly diagnosed patients.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Alergia e Inmunología
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Métodos
Límite:
Animales
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS